Clonal Hematopoiesis, Myeloid Disorders and BAX-Mutated Myelopoiesis in Patients Receiving Venetoclax for CLL

As BCL2 was an important determinant of survival of both myeloid progenitor and B cells, researchers investigated whether clinical and molecular abnormalities arise in the myeloid compartment during long-term continuous venetoclax treatment of chronic lymphocytic leukemia in 89 patients.